Insight Molecular Diagnostics Inc. — Director's Dealing 2022

Mar 17, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2022-03-15

Reporting Person: ANDREWS RONALD ASBURY (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-16	Common Stock, no par value	P	50000	$1.283	Acquired	293212	Direct